Additional file 5: of A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

Ross, Colin; Towfic, Fadi; Shankar, Jyoti; Laifenfeld, Daphna; Thoma, Mathis; Davis, Matthew; Weiner, Brian; Kusko, Rebecca; Zeskind, Ben; Knappertz, Volker; Grossman, Iris; Hayden, Michael

doi:10.6084/m9.figshare.c.3792238_D8.v1

13073_2017_436_MOESM5_ESM.docx (15.72 kB)

Additional file 5: of A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

journal contribution

posted on 2017-05-31, 05:00 authored by Colin Ross, Fadi Towfic, Jyoti Shankar, Daphna Laifenfeld, Mathis Thoma, Matthew Davis, Brian Weiner, Rebecca Kusko, Ben Zeskind, Volker Knappertz, Iris Grossman, Michael Hayden

The eleven-SNP model coefficients, odds ratios with 95% Bayesian confidence intervals and posterior inclusion probabilities. (DOCX 15 kb)

Funding

Teva Pharmaceutical Industries (IL)

History

Usage metrics

Keywords

Pharmacogenetics Copaxone Glatiramer acetate Treatment-response Inter-individual variability Multiple sclerosis Multi-SNP signature Multivariable Bayesian modeling

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 5: of A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

Funding

Teva Pharmaceutical Industries (IL)

History

Usage metrics

Categories

Keywords

Licence

Exports